Changes in the bone and liver isoenzymes of alkaline phosphatase in postmenopausal women being treated with norethisterone

doi:10.1016/0009-8981(88)90295-1

Clinica Chimica Acta

Volume 171, Issue 1, 15 January 1988, Pages 103-108

https://doi.org/10.1016/0009-8981(88)90295-1 Get rights and content

Abstract

The effects of norethisterone therapy on alkaline phosphatase isoenzyme activities were studied in a group of postmenopausal women. There was a significant fall in total alkaline phosphatase activity after 8 wk which was still in evidence after 24 wk. Both bone and liver alkaline phosphatase isoenzyme activities were decreased during the first 16 wk on treatment, but after 24 wk only the bone phosphatase activity was significantly lower than the pretreatment level. The other biochemical indices of bone metabolism and liver function were also measured during the study. The results indicate that bone specific alkaline phosphatase activity is a more sensitive index of bone activity than total alkaline phosphatase and that monitoring of total activity may in some instances be misleading.

References (20)

R Lindsay et al.
Long term prevention of post-menopausal osteoporosis
Lancet
(1976)
DW Moss et al.
A simplified heat-inactivation method for investigating alkaline phosphatase isoenzymes in serum
Clin Chim Acta
(1975)
J Hitz et al.
Automated quantification of bone and liver alkaline phosphatase isoenzymes of human serum
Clin Chim Acta
(1980)
CB Hammond et al.
Current status of oestrogen therapy for the menopause
Fertil Steril
(1982)
C Christiansen et al.
Prevention of early postmenopausal bone loss; controlled 2-year study in 315 normal females
Eur J Clin Invest
(1980)
MEL Paterson
A randomised double-blind crossover trial into the effect of norethisterone on climacteric symptoms and biochemical profiles
Br J Obstet Gynaecol
(1982)
HI Abdalla et al.
Prevention of bone mineral loss in postmenopausal women by norethisterone
Obstet Gynecol
(1985)
C Christiansen et al.
Pathophysiological mechanisms of oestrogen effect on bone metabolism. Dose response relationship in early postmenopausal women
J Endocrinol Metab
(1982)
RW Marshall et al.
The effect of ethinyl oestradiol on calcium and bone metabolism in peri- and postmenopausal women
Horm Metab Res
(1984)
RG Crilly et al.
Rise in plasma alkaline phosphatase at the menopause
Clin Sci
(1980)

There are more references available in the full text version of this article.

Cited by (7)

The progesterone antagonist, RU486 does not affect basal or estrogen-stimulated cancellous bone formation in the rat
1992, Bone and Mineral
Although it has been suggested that progesterone may have a role in preventing postmenopausal bone loss, a number of studies have shown that progesterone has no additive effect on estrogen therapy. We have recently found that high-dose estrogen stimulates bone formation in rats. The effect of progesterone on this anabolic action of estrogen has not been tested. We therefore investigated the role of progesterone in combination with endogenous or exogenous estrogen on bone formation in rats using RU486, which has been shown to be a potent progesterone antagonist without detectable agonist effects. Three-month-old Wistar female rats were treated for 17 days with RU486, and histomorphometric indices of bone formation were measured at the proximal tibial metaphysis after administration of double fluorochrome labels. Animals treated with RU486 (10 mg/kg) showed no change in either bone formation rate or double-labelled bone surfaces compared to vehicle-treated controls. Estrogen (17β-estradiol, 4 mg/kg) increased both indices by more than double compared with controls. RU486 did not affect the indices of increased bone formation in estrogen-treated rats. Estrogen also exhibited inhibition of longitudinal bone growth, while RU486 had no effect either in normal or estrogen-treated animals. These results show that the progesterone antagonist affects neither the stimulatory effect on formation nor the inhibitory effect on longitudinal bone growth by estrogen. These results suggest that progesterone does not play a significant role in either bone formation or bone growth in the rat.
Sex steroids and osteoporosis: Effects of deficiencies and substitutive treatments
1990, Journal of Steroid Biochemistry and Molecular Biology
Adult mammalian bone is continuously renewed by the process of remodelling. In young healthy adults the amount of bone that is resorbed by osteoclasts is replaced by osteoblasts so that no net loss of bone occurs. In a situation of reduced sex hormone levels, such as in females after menopause or ovariectomy, in males after orchidectomy, or in patients of either sex with gonadal dysfunction, there is an imbalance between bone resorption and bone formation resulting in bone loss. The various hypotheses to explain the aetiology of this imbalance are reviewed.
Substitution therapy of females with oestrogen results in the prevention of oestrogen deficiency-induced bone loss. It is generally agreed that the effect is due to inhibition of bone resorption. Recent in vitro data, however, indicate that oestrogens also have the capacity to stimulate the proliferation and functioning of bone-forming cells. Prevention of oestrogen deficiency-induced bone loss can also be achieved by treatment with high doses of progestagens. Available data suggest that this too is caused by resorption inhibition.
The aim of treatment of females, who have lost so much bone that there is an increased risk of fractures after minimal trauma, is to increase bone mass rather than to prevent further bone loss. This can be accomplished by treatment with anabolic steroids. Both biochemical and histological data indicate that anabolics stimulate the activity of functioning osteoblasts. The increase in bone mass during continuous treatment is temporary because anabolics most probably also inhibit bone resorption. Substitution therapy with anabolics or androgens in males is equally effective and increases trabecular bone mass in the spine.
Progestins and tissue effects of hormone replacement therapy: Action on bone and the cardiovascular system
2002, Reproduction Humaine et Hormones
Picomolar norethindrone in vitro stimulates the cell proliferation and activity of a human osteosarcoma cell line and increases bone collagen synthesis without an effect on bone resorption
1994, Journal of Bone and Mineral Research
High‐Dose gestagens modulate bone resorption and formation and enhance estrogen‐induced endosteal bone formation in the ovariectomized mouse
1993, Journal of Bone and Mineral Research
Progesterone as a bone-trophic hormone
1990, Endocrine Reviews

View all citing articles on Scopus

View full text

Changes in the bone and liver isoenzymes of alkaline phosphatase in postmenopausal women being treated with norethisterone

Abstract

Lancet

Clin Chim Acta

Clin Chim Acta

Current status of oestrogen therapy for the menopause

Fertil Steril

Prevention of early postmenopausal bone loss; controlled 2-year study in 315 normal females

Eur J Clin Invest

A randomised double-blind crossover trial into the effect of norethisterone on climacteric symptoms and biochemical profiles

Br J Obstet Gynaecol

Prevention of bone mineral loss in postmenopausal women by norethisterone

Obstet Gynecol

Pathophysiological mechanisms of oestrogen effect on bone metabolism. Dose response relationship in early postmenopausal women

J Endocrinol Metab

The effect of ethinyl oestradiol on calcium and bone metabolism in peri- and postmenopausal women

Horm Metab Res

Rise in plasma alkaline phosphatase at the menopause

Clin Sci